KM Research Hub

FIXED FIVE-YEAR COHORT AUDIT

近五年文献重新检索与对照

旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。

complete · complete 汇总 CSV 明细 CSV
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1

四个独立队列

数字为批次中保存的原始 PMID 数,不会随着日常监测改变。

历史库存参照组 13065 audit_reference · server-inventory-snapshot-v1
旧查询复现组 7069 primary_legacy · legacy-phase3-fulltext-v1
严格 v3 主组 4707 primary_new · oncology-phase3-survival-strict-v3
v3 广召回影子组 13640 recall_audit · oncology-phase3-survival-discovery-v3

集合关系

交集和差集均按 PMID 精确计算;DOI 只用于明细核对。

比较交集左组独有右组独有
历史库存 ↔ 旧查询复现 7028 6037 41
旧查询复现 ↔ 严格 v3 2464 4605 2243
严格 v3 ↔ 广召回影子组 4707 0 8933
严格查询未命中、但影子组经 v3 筛选后合格 166 篇

元数据入排

20925 / 20925 已完成

KM 证据

仅检查 v3 元数据合格论文,不运行曲线数字化。

论文明细

共 628 篇;可组合筛选集合关系、入排结果和 KM 证据。

论文队列集合关系v3 入排KM 证据
Correlation of PSA and survival in metastatic hormone-sensitive prostate cancer treated with rezvilutamide plus ADT in the CHART trial. PMID 39419035 · Med · 2025-Feb-14 The record describes an exploratory analysis (correlation of PSA and survival) from the CHART trial, which is a randomized controlled trial in metastatic hormone-sensitive prostate cancer. While it is oncology, human, randomized, drug-intervention, and reports time-to-event efficacy data, the phase of the trial is not explicitly stated in the provided metadata. The deterministic review also flagged 'phase3_evidence_unclear'. Therefore, the phase criterion cannot be definitively established as Phase III/IIIb or Phase II/III.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
JCCG ALL-B12: Evaluation of Intensified Therapies With Vincristine/Dexamethasone Pulses and Asparaginase and Augmented High-Dose Methotrexate for Pediatric B-ALL. PMID 39531610 · J Clin Oncol · 2025-Feb-10 The record meets most criteria (oncology, human, randomized, drug intervention, time-to-event endpoint, original result) but the explicit trial phase (Phase III/IIIb or Phase II/III) is not established in the provided metadata. Therefore, the 'phase3_or_definitive' criterion cannot be set to true, making the overall eligibility false.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Randomized phase III study comparing re-irradiation stereotactic body radiotherapy and conventional radiotherapy for painful spinal metastases: Japan Clinical Oncology Group study JCOG2211 (RESCORE study). PMID 39431960 · Jpn J Clin Oncol · 2025-Feb-04 The record is a protocol for a Phase III randomized oncology trial comparing radiotherapy techniques for painful spinal metastases. It meets the criteria for oncology, human, randomized, and phase3_or_definitive. However, it lacks a drug-containing intervention (radiotherapy is a device/modality, not a drug), and the abstract is a protocol without reported results. The primary endpoint (pain response at 12 weeks) could be considered a time-to-event endpoint in principle, but the abstract does not explicitly report time-to-event results (e.g., Kaplan-Meier, HR), and the deterministic_review signals 'time_to_event: false' and 'drug_intervention: false'. Therefore, it is excluded as not meeting the drug intervention requirement and lacking explicit time-to-event result reporting.
H S B
严格 v3 独有 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Rationale and design of a multicentre randomised controlled trial on circulating tumour DNA-guided neoadjuvant treatment strategy for locally advanced rectal cancer (CINTS-R). PMID 39894522 · BMJ Open · 2025-Feb-02 This is a clinical trial protocol for a randomized controlled trial. While it meets criteria for oncology, human, randomized, time-to-event endpoints, and drug intervention, it is not a formal report of trial results. The trial phase is not explicitly stated in the title, abstract, or metadata as Phase III/IIIb or Phase II/III, and the deterministic review flagged phase3_evidence_unclear. Therefore, it is excluded as a protocol-without-results and due to insufficient evidence for the required phase.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
REZILIENT3: randomized phase III study of first-line zipalertinib plus chemotherapy in patients with EGFR exon 20 insertion-mutated NSCLC. PMID 39957151 · Future Oncol · 2025-Feb The publication is a clinical trial protocol for an ongoing phase III randomized study in oncology with a drug intervention. It describes the study design but does not present results or data, so time-to-event efficacy endpoints (e.g., OS, PFS) cannot be assessed from the abstract. It is excluded as a protocol without results.
H B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Correction to "Nivolumab Plus Chemotherapy or Ipilimumab Versus Chemotherapy in Patients With Advanced Esophageal Squamous Cell Carcinoma (CheckMate 648): 29-Month Follow-Up From a Randomized, Open-Label, Phase III Trial". PMID 39927664 · Cancer Med · 2025-Feb The record is for a published erratum to a Phase III trial abstract, but the abstract content is missing. While the title indicates a 29-month follow-up from a randomized, open-label, Phase III trial (CheckMate 648) in esophageal squamous cell carcinoma with a drug-containing intervention, the absence of the abstract prevents confirmation of a time-to-event efficacy endpoint (e.g., OS, PFS, HR, Kaplan-Meier) and whether this is an original result report. The publication type is an erratum, which is not a primary research report.
H B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Evaluation of circulating tumor DNA as a prognostic and predictive biomarker in BRAF V600E mutated colorectal cancer-results from the FIRE-4.5 study. PMID 39630848 · Mol Oncol · 2025-Feb The record is an eligible oncology RCT with drug intervention and time-to-event endpoints, but it is a pre-specified translational/biomarker analysis of a subgroup within a larger trial, not the primary formal result report of the overall Phase III trial.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
A phase III randomised trial on the addition of a contact X-ray brachytherapy boost to standard neoadjuvant chemo-radiotherapy for organ preservation in early rectal adenocarcinoma: 5 year results of the OPERA trial. PMID 39532203 · Ann Oncol · 2025-Feb The study is a phase III randomized trial in oncology with a drug intervention, but the primary endpoint is organ preservation rate, a categorical outcome at a fixed time, not a time-to-event endpoint like OS, PFS, or DFS. No Kaplan-Meier curves or hazard ratios for survival or progression are reported or indicated as primary/secondary efficacy outcomes.
H L B
旧查询独有 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Safety and efficacy of up to 60 h of iv istaroxime in pre-cardiogenic shock patients: Design of the SEISMiC trial. PMID 39375885 · ESC Heart Fail · 2025-Feb This is a protocol for a non-oncology (cardiogenic shock) Phase II/III trial. It lacks a time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, HR) and does not report results.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Efficacy, safety and immunogenicity of a recombinant human papillomavirus bivalent (types 16, 18) vaccine in healthy 18-30-year-old Chinese women: a phase III, double-blind, randomized, controlled trial. PMID 41413453 · BMC Infect Dis · 2025-Dec-18 The study is a randomized, placebo-controlled Phase III trial of a drug (HPV vaccine) with an oncology indication (prevention of cervical neoplasia). However, the primary efficacy endpoint is the proportion developing CIN2+, a categorical outcome, not a time-to-event endpoint like OS, PFS, or DFS. No Kaplan-Meier curves, hazard ratios, or other time-to-event analyses are reported in the abstract. Therefore, it does not meet the required time-to-event efficacy endpoint criterion.
H L B
旧查询独有 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
BREAKWATER Phase III: results for encorafenib and cetuximab plus mFOLFOX6 in first-line BRAF V600E-mutant metastatic colorectal cancer. PMID 41230651 · Future Oncol · 2025-Dec Phase III drug trial with time-to-event endpoints, but the provided metadata does not explicitly establish randomization, which is a required criterion for eligibility.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Re: Effect of NeuroSAFE-guided RARP Versus Standard RARP on Erectile Function and Urinary Continence in Patients with Localised Prostate Cancer (NeuroSAFE PROOF): A Multicentre, Patient-blinded, Randomised, Controlled Phase 3 Trial. PMID 40713359 · Eur Urol · 2025-Dec The record is a title-only entry for a Phase 3 randomized trial in oncology. However, it fails multiple eligibility criteria based on available metadata: (1) No abstract or text to confirm a time-to-event efficacy endpoint (time_to_event: false). (2) The intervention described is surgical (RARP) with no explicit drug component (drug_intervention: false). (3) The 'Re:' prefix in the title and absence of abstract suggest this may not be the original primary result publication (original_result: false). Therefore, it is not eligible.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Swallowing and Communication Outcomes Post Chemoradiotherapy for Low-Risk Human Papillomavirus (HPV)-Associated Oropharyngeal Squamous Cell Carcinoma: A Substudy of TROG 12.01. PMID 40662470 · Head Neck · 2025-Dec The study is a substudy of a Phase III randomized trial but reports on swallowing and communication outcomes, not on a primary/key secondary time-to-event efficacy endpoint like OS or PFS. Therefore, it does not meet the inclusion criteria for a Kaplan-Meier digitization cohort.
H L B
旧查询独有 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
High mid-treatment tumour RNA disruption in patients with HER2-negative breast cancer is associated with improved disease-free survival after neoadjuvant chemotherapy. PMID 40790765 · Breast Cancer Res · 2025-Aug-11 The study meets all other criteria but the trial phase is not explicitly stated as Phase III/IIIb or Phase II/III in the provided record. Eligibility requires explicit confirmation of a definitive trial phase.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Erratum: Randomized, Open-Label, Phase III Study of Tilsotolimod in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced Refractory Melanoma (ILLUMINATE-301). PMID 40561410 · J Clin Oncol · 2025-Aug-10 The record is a published erratum for a Phase III trial. While it pertains to an oncology, randomized, drug-intervention study, it is not an original result report. The erratum itself does not provide the primary efficacy data (time-to-event outcomes) needed for inclusion. The deterministic review correctly identified a lack of time-to-event signal.
H
仅历史库存 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Integrative Immune Signature of Complementary Circulating and Tumoral Biomarkers Maximizes the Predictive Power of Adjuvant Immunotherapeutic Benefits in High-risk Melanoma. PMID 40392969 · Clin Cancer Res · 2025-Aug-01 This record is a secondary biomarker analysis of the E1609 Phase III trial, not the original primary result report. While it references a Phase III trial with drug intervention and time-to-event endpoints, it does not present the original trial results. Randomization is implied but not explicitly confirmed in this abstract. Therefore, is_eligible is set to null.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Author Correction: Sasanlimab plus BCG in BCG-naive, high-risk non-muscle invasive bladder cancer: the randomized phase 3 CREST trial. PMID 40691368 · Nat Med · 2025-Aug The record is a published erratum for a trial, not an original result report. Additionally, there is no evidence in the provided metadata of a time-to-event efficacy endpoint being reported.
H B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Facial Skin With Conspicuous Enlarged Pores Closely Related to Severity of Facial Acneiform Rash and Therapeutic Effects of EGFR Inhibitors in RAS Wild-Type Metastatic Colorectal Cancer: Ancillary Analysis of FAEISS Study (NCCH1512). PMID 40503645 · J Dermatol · 2025-Aug The record describes an ancillary analysis of a Phase III randomized trial focusing on skin toxicity markers and disease control rate (a response metric, not a time-to-event outcome). The primary/key secondary endpoint of the parent trial is not specified, and this report does not present Kaplan-Meier curves or hazard ratios for OS, PFS, or other time-to-event endpoints.
H L B
旧查询独有 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Tumoral pSMAD2 as a prognostic biomarker in early-stage breast cancer: insights from the randomized SweBCG91RT trial. PMID 40488800 · Breast Cancer Res Treat · 2025-Aug The record describes a biomarker analysis (pSMAD2) of a randomized trial (SweBCG91RT) comparing radiotherapy vs. no radiotherapy after surgery. The intervention is non-drug (radiotherapy), and the primary endpoint is recurrence risk (ipsilateral breast tumor recurrence and all recurrences). While recurrence is a time-to-event endpoint, the study is explicitly a biomarker-focused prognostic analysis (subgroup/secondary) of a trial with a non-drug intervention. It lacks a drug-containing intervention and does not present a primary time-to-event efficacy analysis for a drug.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
High-dose cytarabine with idarubicin consolidation for acute myeloid leukemia in first complete remission: a randomized controlled trial. PMID 40437173 · Leukemia · 2025-Aug The record describes a randomized, oncology, human, drug-intervention trial that reports time-to-event efficacy endpoints (DFS, OS). However, the provided metadata does not explicitly establish the trial phase as Phase III/IIIb or Phase II/III. The abstract does not mention the phase, and the publication types or MeSH terms do not include a definitive phase designation. Therefore, eligibility cannot be determined without this critical criterion.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Adjuvant Docetaxel Versus Surveillance in Intermediate- or High-risk Prostate Cancer After Radical Curative Radiotherapy: Final Survival Results from the SPCG-13 Trial. PMID 40312180 · Eur Urol Oncol · 2025-Aug The record meets all criteria except explicit confirmation of a definitive phase (Phase III/IIIb or Phase II/III). The study is oncologic, human, randomized, involves a drug intervention, reports original results for a time-to-event primary endpoint, and is a final report. However, the absence of explicit phase information in the provided metadata prevents a definitive eligibility determination, requiring a null is_eligible status.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Circulating tumor DNA strongly predicts efficacy of chemotherapy plus immune checkpoint inhibitors in patients with advanced gastro-esophageal adenocarcinoma. PMID 40275077 · Commun Med (Lond) · 2025-Apr-24 Cannot confirm eligibility because the trial phase is not specified in the abstract, and the report is a biomarker subgroup analysis of a randomized trial, not the primary efficacy report.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
[Clinical efficacy of prostatectomy combined with neoadjuvant endocrine therapy]. PMID 40787958 · Zhonghua Nan Ke Xue · 2025-Apr The record describes a randomized controlled trial in oncology (prostate cancer) with a drug-containing intervention (neoadjuvant endocrine therapy). However, it does not report a primary or key secondary time-to-event efficacy endpoint such as overall survival, progression-free survival, disease-free survival, event-free survival, recurrence-free survival, time to progression, or any Kaplan-Meier or hazard ratio analysis. The outcomes reported are clinical indicators, immune function, serum markers, complications, and a non-formal one-year recurrence rate. Therefore, it does not meet the eligibility requirement for a time-to-event efficacy endpoint. The phase is not explicitly stated, so phase3_or_definitive is null.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
SWOG 2308: Randomized Phase III Study of Mosunetuzumab Versus Rituximab for Low-Tumor Burden Follicular Lymphoma. PMID 40264918 · JCO Oncol Adv · 2025-Apr Record fails required criteria due to missing abstract content, which prevents verification of human subjects and the presence of a time-to-event efficacy endpoint. The title suggests eligibility, but without an abstract, we cannot confirm the report contains original results or that a time-to-event endpoint is reported.
H B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Enzalutamide in biochemically recurrent prostate cancer: key findings from the EMBARK study. PMID 40145508 · Future Oncol · 2025-Apr The record describes a randomized phase 3 oncology trial with human patients and likely drug intervention, and the podcast discusses original results. However, the abstract does not explicitly state a time-to-event endpoint (e.g., OS, PFS) or confirm drug intervention details for strict eligibility. The publication type is also non-standard for formal result reporting.
H S B
严格 v3 独有 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Author Correction: First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trial. PMID 40140623 · Nat Med · 2025-Apr Eligibility cannot be determined because the record is a published erratum (correction) for a trial, not the original result report itself. The provided metadata lacks an abstract or any content describing study outcomes, making it impossible to confirm the presence of a primary/key secondary time-to-event efficacy endpoint, which is a required criterion for inclusion. Metadata does not establish human subject participation.
H B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Enzalutamide in biochemically recurrent prostate cancer: design and rationale of the EMBARK study. PMID 40130421 · Future Oncol · 2025-Apr The record is an eligible-type trial (Phase III, randomized, drug intervention, oncology, human) but is a podcast discussing design and rationale, not an original formal result report with a time-to-event efficacy endpoint. Therefore, it is excluded as not meeting the 'original_result' criterion and lacking a 'time_to_event' signal in this record.
H S B
严格 v3 独有 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Author Correction: Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trial. PMID 39948407 · Nat Med · 2025-Apr The record is a published erratum/correction for a phase 3 trial (CEPHEUS). While the underlying trial meets the oncology, phase 3, randomized, and drug intervention criteria, the provided record is not an original result report and lacks any explicit time-to-event efficacy endpoint data. Therefore, eligibility cannot be confirmed, and it is excluded.
H B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Meaningful change threshold estimation for the non-small cell lung cancer symptom assessment questionnaire (NSCLC-SAQ): psychometric analysis from a phase 3 trial (LIBRETTO-431). PMID 39847268 · Qual Life Res · 2025-Apr The record describes a psychometric analysis of a patient-reported outcome questionnaire from a Phase 3 randomized trial, but it does not report any primary or key secondary time-to-event efficacy endpoint (OS, PFS, DFS, etc.) or Kaplan-Meier/HR results, and it does not explicitly specify a drug intervention. Therefore, it does not meet the eligibility criteria for a drug-intervention oncology trial with time-to-event efficacy.
H L B
旧查询独有 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Gut microbiota diversity is prognostic and associated with benefit from chemo-immunotherapy in metastatic triple-negative breast cancer. PMID 39545921 · Mol Oncol · 2025-Apr The record describes a biomarker-focused secondary analysis of the ALICE trial, investigating the prognostic and predictive value of gut microbiota. While it references a randomized trial with a drug intervention and a PFS endpoint, the abstract does not state the trial's phase, and the report's primary focus is not the formal reporting of the trial's primary efficacy results. Therefore, it does not meet the criteria for an original, primary result report of a definitive-phase trial.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Mechanism of an integrated PBL-KAP-AI spiral health education model for breast cancer patients. PMID 41404555 · Front Public Health · 2025 The study is a randomized trial in oncology (breast cancer) with original results. However, it is excluded because it is not a Phase III/IIIb or Phase II/III trial (phase is not specified and cannot be inferred), it does not involve a drug-containing intervention (it evaluates a health education model), and its primary outcomes (health behaviors, beliefs, quality of life) are not time-to-event endpoints (OS, PFS, DFS, etc.) with Kaplan-Meier or HR analysis.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Effect of preoperative oral carbohydrate combined with postoperative early enteral nutrition on the perioperative rehabilitation of patients with colorectal cancer: a multicenter randomized controlled trial. PMID 41393952 · Front Nutr · 2025 The study is a randomized trial in colorectal cancer patients. It reports on perioperative recovery outcomes (e.g., time to first exhaust, hospitalization length) but does not report on a time-to-event efficacy endpoint such as OS, PFS, DFS, or Kaplan-Meier survival analysis. The intervention (preoperative oral carbohydrates and postoperative early enteral nutrition) is non-drug, not a therapeutic anti-neoplastic drug. The trial phase is not specified in the record.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Effect of perioperative ONS combined with intestinal microecology in patients with colorectal cancer: a randomized clinical trial. PMID 40497027 · Front Nutr · 2025 The record is a randomized trial in human oncology patients with a drug-containing intervention (ONS + probiotic) and reports primary results. However, it lacks a primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS) as required by the cohort definition. The endpoints are nutritional status, inflammation, and intestinal function recovery. Additionally, the trial phase is not explicitly stated as Phase III/IIIb or Phase II/III.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
The ReDyor study: Effects of prophylactic swallowing exercises on dysphagia and quality of life in patients with head and neck cancer receiving chemoradiation therapy, a randomized clinical trial. PMID 40179796 · Rehabilitacion (Madr) · 2025 The study is a randomized clinical trial in head and neck cancer patients, but it is not Phase III/IIIb or Phase II/III. It does not contain a drug-containing intervention (exercise-based). It does not report a primary/key secondary time-to-event efficacy endpoint (OS, PFS, etc.) or Kaplan-Meier analysis.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Application of the end-of-life demands card game and mindfulness-based cancer recovery program for reducing negative emotion in patients with advanced lung cancer: a randomized controlled trial. PMID 40177032 · Front Psychol · 2025 The study is a randomized trial in advanced lung cancer patients, but it evaluates psychosocial interventions (a card game and mindfulness program), not a drug. The endpoints are psychometric scales (death anxiety, depression, stress), not time-to-event outcomes (e.g., OS, PFS).
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Randomized Trial of Fixed-Dose Capecitabine Compared With Standard-Dose Capecitabine in Metastatic Breast Cancer: X-7/7 Trial. PMID 39917581 · JCO Oncol Adv · 2025 The record describes a randomized trial with a drug intervention and time-to-event efficacy endpoint in oncology, but the trial phase is not explicitly stated in the provided metadata or abstract. The deterministic review notes phase evidence is unclear. Without explicit confirmation of Phase III/IIIb or Phase II/III status, the record cannot be considered eligible.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
A Commensurate Prior Model With Random Effects for Survival and Competing Risk Outcomes to Accommodate Historical Controls. PMID 39846144 · Pharm Stat · 2025 The record describes a statistical methodology paper that applies a model to a phase III clinical trial, but it is not the original formal-result report of the trial itself. The application is to a non-drug intervention (bone marrow/cord blood transplant). No time-to-event efficacy endpoint (e.g., OS, PFS, HR, Kaplan-Meier) is explicitly reported in the abstract.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Clinical Study of Tuhuanglian Liquid Wet Compress on Acute Radiation Dermatitis of Nasopharyngeal Carcinoma. PMID 39612268 · Crit Rev Biomed Eng · 2025 The study is a randomized trial in oncology patients with a drug intervention (Tuhuanglian liquid wet compress), but it does not report a time-to-event efficacy endpoint such as OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier curves, or hazard ratios. The primary outcome is the severity (RTOG grading) and time to develop grade 3 dermatitis, which is a toxicity/safety endpoint, not an efficacy endpoint. The trial phase is not specified in the record.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
On-treatment biopsies to predict response to neoadjuvant chemotherapy for breast cancer. PMID 39317942 · Breast Cancer Res · 2024-Sep-24 The record describes a secondary, biomarker-focused analysis pooling data from three separate randomized trials (GeparQuattro, GeparQuinto, GeparSixto). While the underlying trials are likely Phase III, the publication itself is not the primary efficacy report of a single trial. The study's primary goal is to correlate on-treatment biopsies with pathologic complete response and disease-free survival, not to report the definitive trial outcome. Therefore, it does not meet the inclusion criteria for an original formal-result report of a single Phase III/IIIb or Phase II/III randomized trial.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Modified Banxiaxiexin decoction benefitted chemotherapy in treating gastric cancer by regulating multiple targets and pathways. PMID 38697407 · J Ethnopharmacol · 2024-Sep-15 The record describes a randomized, controlled trial in human gastric cancer patients with drug intervention and OS/PFS endpoints, consistent with a definitive trial. However, the trial phase (Phase III/IIIb or Phase II/III) is not explicitly stated in the provided metadata or abstract, making it impossible to definitively confirm phase eligibility. The 'deterministic_review' also flags phase evidence as unclear.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Impact of Perioperative Lidocaine on Neutrophil Extracellular Trapping and Serum Cytokines in Robot-Assisted Radical Prostatectomy: Randomized Controlled Study. PMID 39336493 · Medicina (Kaunas) · 2024-Sep-05 The study is a randomized controlled trial in oncology (prostate cancer) and reports original results. However, it is excluded because: (1) the intervention is perioperative lidocaine, which is not a systemic anticancer drug intervention as required; (2) the primary endpoint, biochemical recurrence (BCR), is not a time-to-event efficacy endpoint (OS, PFS, DFS, etc.) with reported Kaplan-Meier or hazard ratio analysis; (3) the trial phase is not specified as Phase III/IIIb or definitively established as such.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Comparison between Trans-Arterial Chemoembolization Followed by Stereotactic Body Radiation Therapy and Trans-Arterial Chemoembolization Alone in BCLC Stage B Hepatocellular Carcinoma: A Pilot Study. PMID 39342585 · Asian Pac J Cancer Prev · 2024-Sep-01 The study is an oncology randomized trial with time-to-event endpoints, but it is ineligible due to: 1) No drug-containing intervention (the intervention is TACE±SBRT, which are locoregional procedures, not systemic drug therapy); 2) Phase evidence is insufficient (publication type includes 'Pilot Projects', suggesting it may be Phase II, not definitively Phase III/IIIb or II/III).
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Efficacy of CalliSpheres® drug-loaded microspheres combined with doxorubicin in hepatocellular carcinoma. PMID 39154241 · Scand J Gastroenterol · 2024-Sep The record is a randomized, human oncology trial with a drug intervention and time-to-event endpoints. However, the explicit trial phase (e.g., Phase III, Phase II/III) is not stated in the provided metadata or abstract. The 'publication_types' do not specify a definitive phase, and the 'deterministic_review' signal indicates phase evidence is unclear. Therefore, eligibility cannot be confirmed as true because the phase criterion is not explicitly established.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Patient Experiences of Specialty Palliative Care in the Perioperative Period for Cancer Surgery. PMID 38906425 · J Pain Symptom Manage · 2024-Sep This is a qualitative interview study embedded within a randomized controlled trial, focusing on patient experiences of palliative care in the perioperative period. It is not a report of the trial's primary efficacy results. It lacks a drug intervention and a time-to-event efficacy endpoint (OS, PFS, etc.).
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Within-trial hospitalization resource utilization and budget impact analysis for darolutamide in metastatic hormone-sensitive prostate cancer using ARASENS. PMID 38807035 · J Manag Care Spec Pharm · 2024-Sep While the study is a randomized phase 3 trial in oncology with a drug intervention, it is not eligible because it does not report a time-to-event efficacy endpoint. The analysis is a health-economic/budget impact study, which is excluded per the criteria.
H L B
旧查询独有 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
A 3-arm randomized control trial to compare the efficacy of re-circulant hyperthermic intravesical chemotherapy versus conventional intravesical mitomycin C and BCG therapy for intermediate-risk non-muscle invasive bladder cancer. PMID 39480527 · World J Urol · 2024-Oct-31 The record describes a randomized trial with a drug-containing intervention and a time-to-event efficacy endpoint (time to recurrence). However, the publication metadata and abstract do not explicitly state the trial phase (Phase III/IIIb or Phase II/III). Without this information, eligibility cannot be confirmed.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Regression and growth rates in androgen deprivation therapy for advanced castration-sensitive prostate cancer. PMID 39472345 · World J Urol · 2024-Oct-29 The record describes a subgroup analysis of a randomized trial comparing ADT regimens. While it is oncologic, human, randomized, and reports time-to-event efficacy endpoints, it is not the primary report of the trial's main results. The phase of the underlying trial (KYUCOG-1401) is not explicitly confirmed as Phase III/IIIb or Phase II/III in the provided metadata, and the report type is secondary. Therefore, eligibility cannot be fully established.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Inetetamab combined with S-1 and oxaliplatin as first-line treatment for human epidermal growth factor receptor 2-positive gastric cancer. PMID 39494102 · World J Gastroenterol · 2024-Oct-28 The study is a randomized trial with a drug intervention and reports time-to-event efficacy endpoints. However, the abstract does not explicitly state the trial phase (e.g., Phase III, Phase IIIb, or Phase II/III). The deterministic review flagged 'phase3_evidence_unclear'. Since the phase is not explicitly confirmed in the provided metadata, eligibility cannot be definitively established.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Estrogen Plus Progestin and Colorectal Cancer: Long-Term Findings From the Women's Health Initiative Randomized Clinical Trial. PMID 39028918 · J Clin Oncol · 2024-Oct-20 While the record describes a human randomized trial with a drug intervention and reports a time-to-event endpoint (colorectal cancer death HR), the primary endpoint of the trial (colorectal cancer incidence) is not the key efficacy endpoint for the drug's intended use. The report is a secondary analysis/update on a specific outcome from a large, multifactorial preventive trial (WHI), not a definitive oncology Phase III trial for a therapeutic drug. The trial phase is also not confirmed as Phase III in the metadata.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Efficacy and safety of infliximab or adalimumab in severe mucocutaneous Behçet's syndrome refractory to traditional immunosuppressants: a 6-month, multicentre, randomised controlled, prospective, parallel group, single-blind trial. PMID 39419537 · Ann Rheum Dis · 2024-Oct-17 The trial is for Behçet's syndrome, an autoimmune/inflammatory condition, not a human malignant neoplasm. While it meets several criteria (human, randomized, Phase III, drug intervention, original result), it is excluded because it is not an oncology study.
H S B
严格 v3 独有 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -